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Emodin ameliorates glucose-induced matrix synthesis in hu-
man peritoneal mesothelial cells.
Background. Prolonged exposure of human peritoneal meso-
thelial cells (HPMC) to high glucose concentrations in perito-
neal dialysate is the principal factor leading to matrix accumula-
tion and thickening of the peritoneal membrane, accompanied
by progressive deterioration of transport functions. These changes
are mediated in part through protein kinase C (PKC) activation
and the induction of transforming growth factor-beta 1 (TGF-1).
Emodin (3-methyl-1,6,8 trihydroxyanthraquinone) has pre-
viously been demonstrated to reduce cell proliferation and
fibronectin synthesis in cultured mesangial cells. How emodin
modulates glucose-induced abnormalities in HPMC has not
been elucidated and thus constitutes the theme of this study.
Methods. We investigated the effects of emodin on the ex-
pression of PKC, TGF-1, fibronectin, and collagen type I in
HPMC, and its effects on HPMC proliferation under physio-
logic (5 mmol) or high (30 mmol) glucose concentrations.
Results. Exposure of HPMC cultured with 5 mmol or 30
mmol D-glucose to emodin (20 g/mL) resulted in an initial
lag of proliferation by 2.3 to 2.7 days, but did not affect cell
viability or morphology at confluence. D-glucose (30 mmol) in-
duced TGF-1 secretion in a time-dependent manner (3.72 
0.29 and 4.30  0.50 pg/g cellular protein at 24 hours and 48
hours respectively, compared to 2.13  0.23 and 2.65  0.32
pg/g cellular protein at 24 hours and 48 hours, respectively
for 5 mmol glucose; P  0.001 at both time points). Such
induction was ameliorated by emodin (20 g/mL) (TGF-1
concentration 2.25 0.15 and 2.96 0.33 pg/g cellular protein
at 24 hours and 48 hours, respectively, in the presence of emo-
din and 30 mmol D-glucose; P  0.001 compared to 30 mmol
D-glucose alone at both time points). Induction of TGF-1 syn-
thesis by 30 mmol D-glucose was associated with induction of
PKC, phosphorylation of cAMP-responsive element binding
protein (CREB) and activating transcription factor-1 (ATF-1),
and increased fibronectin and type I collagen translation. Emo-
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din abrogated all these effects of concentrated glucose. Immu-
nohistochemical staining showed that 30 mmol D-glucose in-
duced cytoplasmic, perinuclear, and extracellular fibronectin
and type I collagen expression by HPMC. Emodin reduced 30
mmol D-glucose-induced cytoplasmic and extracellular matrix
synthesis to near basal levels.
Conclusion. Our findings demonstrate that emodin amelio-
rates the undesirable effects of concentrated glucose on HPMC
via suppression of PKC activation and CREB phosphorylation,
and suggest that emodin may have a therapeutic potential in
the prevention or treatment of glucose-induced structural and
functional abnormalities in the peritoneal membrane.
The peritoneal membrane provides a protective ana-
tomical barrier and a frictionless interface for the move-
ment of organs and tissues in the peritoneal cavity. Its
constituents include an uppermost protective monolayer
of mesothelial cells, a basal lamina, and the submesothel-
ium, which contains capillaries, fibroblasts, and collage-
nous fibrous tissue [1]. Peritoneal thickening and fibrosis
can result from bacterial infection, surgery, or chemical
or metabolic toxicity, either indirectly through the induc-
tion of pro-inflammatory cytokines and growth factors,
or directly through modulations in the synthesis and/or
degradation of extracellular matrix [2–4]. Mesothelial
cells play a critical role in the synthesis and remodeling
of the extracellular matrix and contribute to the synthesis
of cytokines and growth factors within the peritoneal
cavity [3, 5–7]. Injury to mesothelial cells represents an
important step in the initiation of pathologic changes in
the peritoneal membrane.
Peritoneal dialysis (PD) is an important treatment for
patients with end-stage renal failure. Conventional peri-
toneal dialysates are not physiologic, and they utilize glu-
cose at high concentrations to provide the osmotic drive
for the removal of excessive fluid from the body. Contin-
uous prolonged exposure of the peritoneal membrane
to peritoneal dialysate leads to chronic activation of the
mesothelium, with increased synthesis and secretion of
pro-inflammatory mediators and increased deposition of
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matrix proteins [8, 9]. These processes are further exacer-
bated during episodes of peritonitis. The peritoneum
thus undergoes progressive structural and functional de-
terioration, leading ultimately to failure of PD [10–12].
We, and others, have investigated the role of mesothe-
lial cells in the pathogenesis of peritoneal fibrosis. In vitro
studies have demonstrated that high glucose concentra-
tions can modulate cell proliferation and up-regulate
matrix protein synthesis in peritoneal mesothelial cells.
These changes are mediated by protein kinase C (PKC)
activation and the induction of transforming growth fac-
tor-beta 1 (TGF-1) synthesis [13–15]. PKC is a serine-
threonine kinase that plays a key role in intracellular
signal transduction of hormones and cytokines [16]. It
has at least 12 isoforms, and it remains unclear which
isoforms are involved in the induction of matrix synthesis
and TGF-1 in peritoneal mesothelial cells during long-
term PD. Given that TGF-1 induction is similarly ob-
served in diabetes mellitus, we postulate that PKC,
an isoform well documented to be activated in diabetic
nephropathy [17], may also play a pivotal role in glucose-
induced TGF-1 expression in peritoneal mesothelial
cells.
While TGF-1 is vital to normal tissue repair, overex-
pression of TGF-1 has been strongly implicated as a
major pathogenetic mechanism leading to tissue fibrosis
in different diseases [3, 18]. Previous attempts to alleviate
TGF-1–mediated fibrosis have included the intraperito-
neal administration of glycosaminoglycans, systemic ad-
ministration of anti-TGF-, or blockade of angioten-
sin II by angiotensin-converting enzyme (ACE) inhibitors
[19–22]. Emodin (3-methyl-1,6,8 trihydroxyanthraqui-
none), a natural anthraquinone extracted from Rheum,
has been demonstrated to reduce fibronectin (FN) syn-
thesis in TGF-1–stimulated mesangial cells, and reduce
renal hypertrophy in rats with streptozotocin-induced
diabetic kidney disease [23, 24]. In addition, emodin in-
hibits tyrosine kinase activity and possesses anti-inflam-
matory and anti-proliferative properties [25–29]. In this
context, studies have shown that emodin could reduce
protein-tyrosine phosphorylation in bronchial epithelial
cells, inhibit NF-kappaB (NFB) activation in endothe-
lial cells, reduce proliferation and cytokine synthesis in
mesangial cells and activated T cells, and initiate bacte-
rial DNA damage [25–28]. Given the pivotal role of meso-
thelial cells in peritoneal inflammation and fibrosis dur-
ing PD, and their constant exposure to the high dialysate
glucose concentration, we have been investigating the
effects of high glucose concentration on human perito-
neal mesothelial cells (HPMC) and potential modulatory
mechanisms. We have reported that emodin ameliorated
the morphologic changes and chronic FN synthesis in
HPMC induced by 30 mmol D-glucose [30]. The present
study examined the effects of concentrated glucose on
HPMC proliferation and TGF-1, as well as matrix [FN
and collagen type I (Coll-I)] synthesis by HPMC. We
also investigated the possible role of PKC in mediating
the profibrotic processes, and the mechanisms by which
emodin modulated these glucose-induced changes. Since
elevated glucose concentrations and TGF-1 have been
shown to regulate FN transcription in human mesangial
cells through a consensus cAMP response element (CRE)
located at –170 bp of the FN gene [31, 32], and PKC
can activate CRE-binding protein (CREB) [32], we also
investigated CREB phosphorylation in HPMC under
high glucose concentration in the presence or absence
of emodin. Our results showed that emodin ameliorated
glucose-induced TGF-1 and matrix synthesis in HPMC
by inhibiting PKC activation and phosphorylation of
CREB.
METHODS
Materials
All chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO, USA) unless otherwise stated and
were of the highest purity. Tissue culture flasks were
purchased from Falcon (Becton Dickinson, Hong Kong)
and culture media and supplements from Invitrogen
Hong Kong Ltd. (Hong Kong, China). Antisera to hu-
man FN (clone IST-4), Coll-I (clone COL-1 or C-18),
TGF-1 (sc-146), PKC (clone MC5), and actin (sc-8432)
were purchased from Sigma Chemical Co. and TWC
BioSearch International (Santa Cruz, CA, USA). The
PhosphoPlus CREB (Ser133) antibody kit (New En-
gland BioLabs, Beijing, China; TWC Biosearch Interna-
tional) was used to detect CREB and phosphoCREB.
Tyrosine kinase assay kit was purchased from Sigma
Chemical Co. Cytotoxicity detection kit [lactate dehy-
drogenase (LDH)] was purchased from Boehringer
Mannheim (Roche Diagnostics GmbH, Mannheim, Ger-
many). [3H]-thymidine (methyl-[3H-thymidine) was pur-
chased from Amersham Biosciences China Limited
(Hong Kong, China). Emodin was extracted from Rheum
officinale and fraction-distilled to above 98% purity, and
characterized by high-performance liquid chromatogra-
phy (HPLC), nuclear magnetic resonance (NMR), and
mass spectrometry [33]. Endotoxin-free emodin was dis-
solved in 0.1 mol/L NaOH at a stock concentration of
4 mg/mL, and diluted in Medium 199 prior to use in
experiments. Human umbilical vascular endothelial cells
(HUVEC) and normal human bronchial epithelial cells
(NHBE) were purchased from Clonetics (San Diego, CA,
USA), and human pleural mesothelial cells (MeT-5A) and
mink lung epithelial cells (MLEC; CCL-64) were pur-
chased from American Type Culture Collection (ATCC)
(Manassas, VA, USA).
Cytochemical analysis of peritoneal biopsies
Parietal peritoneal biopsies were obtained from 5 pa-
tients at the time of initial insertion of the PD catheter,
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and from 8 patients who had been on PD for more than
12 months after informed consent, at the time of removal,
or reinsertion of the peritoneal dialysis catheter. Paraffin
sections (10m) were incubated with primary antibodies
against human FN, Coll-I, or TGF-1 (1:50 for all anti-
bodies) overnight at room temperature, and incubated
with relevant secondary antibodies conjugated to horse-
radish peroxidase for 1 hour at 37C. Signal detection
and visualization was achieved using the peroxidase-anti-
peroxidase (PAP) method (Dako; Gene Company, Ltd.,
Hong Kong, China), counterstained with hematoxylin,
and specimens examined using a Leica DMLB micro-
scope (Leica Microsystems, Ltd., Hong Kong, China).
Specimens were photographed with Kodak Max 100 film
using a MPS60 camera.
Culture of cells
HPMC were obtained by enzymatic digestion of omen-
tal specimens from nonuremic patients who underwent
abdominal surgery, and cultured in Medium199 supple-
mented with 10% fetal calf serum (FCS) as previously
described [5, 6]. All experiments were performed on cells
of the second passage that had been growth arrested for
72 hours. After synchronization of the cell cycle, HPMC
were cultured under physiologic D-glucose concentra-
tion (5 mmol), or elevated D-glucose concentration (30
mmol) for periods up to 1 week, or exposed to phorbol
12-myristate 13-acetate (PMA) (100 nmol) for up to 48
hours, in the presence or absence of emodin (20 g/mL).
D-glucose (30 mmol) represented the intraperitoneal
glucose concentration after 1 hour of equilibration fol-
lowing the instillation of conventional peritoneal dialy-
sate, which contained glucose at 75 mmol or 120 mmol.
Mannitol or L-glucose was used as hexose control in
parallel experiments, at concentrations identical to those
of D-glucose. In separate experiments, TGF-1 neu-
tralizing antibody (1 g/mL) was added to HPMC 1 hour
prior to stimulation by elevated glucose or PMA. Human
peritoneal fibroblasts (HPF) were cultured according to
the method of Beavis et al [34], and human mesangial
cells (HMC), glomerular epithelial cells (GEC), and
proximal tubular epithelial cells (PTEC) by differential
sieving of nephrectomized renal specimens [35–37].
Assessment of cell proliferation
[3H]-thymidine incorporation. Cells were seeded into
96-well plates at a density of 10,000/cm2 and cultured in
Medium 199 containing 10% FCS until 80% confluent.
Cells were washed twice with PBS to remove unattached
cells and further incubated with Medium 199 containing
either 5 mmol or 30 mmol D-glucose and [3H]-thymidine
(1 Ci/mL) in the presence or absence of emodin (0 to
200g/mL) for 24 hours. At the end of the time point, the
supernatant was decanted, cells trypsinized with 0.05%
trypsin/0.02% ethylenediaminetetraacetic acid (EDTA),
incorporated radioactivity precipitated with 10% trichlo-
roacetic acid (TCA) (100 L), washed twice with TCA,
and dissolved with 0.1 mol NaOH (200 L). [3H]-thymi-
dine incorporation was detected by beta liquid scintilla-
tion counting.
Direct cell counting. Cells were seeded into 24-well
plates at a density of 10,000/cm2 and cultured for 24 hours
in Medium 199 containing 10% FCS. Cells were washed
twice with PBS to remove unattached cells and further
incubated with Medium 199 containing either 5 mmol or
30 mmol D-glucose in the presence or absence of emodin
for periods up to 7 days. At selective time periods, HPMC
were trypsinized as described above, and counted using
a Neubauer chamber (Sigma Chemical Co.).
Determination of lactate dehydrogenase (LDH) release
Confluent HPMC were cultured under control and ex-
perimental conditions in 96-well tissue culture plates for
24 hours. Supernatants were collected, centrifuged for
10 minutes at 2000g, and assessed for LDH release using
a commercially available cytotoxicity kit according to
the manufacturer’s instructions. Cytotoxicity of control
and experimental samples were expressed as the percent-
age of LDH release compared to total intracellular LDH
content, the latter determined by lysis of representative
cell monolayers using 2% Triton X-100 (vol/vol) according
to the manufacturer’s instructions.
Measurement of cellular protein concentration
HPMC cultured in triplicate in 96-well plates under
control or experimental conditions were lysed with 4 mol
urea buffer, 20 mmol sodium acetate, pH 6.0 containing
1% (vol/vol) Triton X-100 (50 L). Protein concentra-
tion in cell lysate was determined using a modified Lowry
assay according to the manufacturer’s instructions (Bio-
Rad Pacific, Ltd., Hong Kong, China).
Determination of TGF-1 concentration in
culture supernatant
Samples (1 mL) of culture supernatant were lyophi-
lized, reconstituted to 200 L in PBS containing 1%
fatty acid free bovine serum albumin (BSA), and assayed
using a commercial TGF-1 enzyme-linked immunosor-
bent assay (ELISA) kit according to the manufacturer’s
instructions (Onwon Trading, Ltd., Hong Kong). Cross-
reactivity with other TGF- isoforms was less than 2%.
Determination of TGF-1 bioactivity
The mink lung epithelial cell (MLEC) bioassay for
TGF-1 was performed as described by Ha and col-
leagues [13] with slight modification. Briefly, MLEC
(passage 50–55) were subcultured into 96-well culture
plates at 10,000 cells/cm2 and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FCS
for 2 to 4 hours. MLEC were then exposed to serially
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diluted recombinant human TGF-1 (0 to 1000 pg/mL)
or spent culture media from HPMC obtained under con-
trol and experimental conditions for 72 hours at 37C.
Thereafter, [3H]-thymidine (1 Ci/mL) was added to
each well and the incubation continued for another 24
hours. At the end of the incubation period, cells were
washed three times with ice-cold PBS, trypsinized with
0.05% trypsin/0.02% EDTA, incorporated radioactivity
precipitated with 10% TCA (100 L), washed twice with
TCA, and dissolved with 0.1 mol NaOH (200 L). [3H]-
thymidine incorporation was detected by beta liquid
scintillation counting. A standard curve was constructed
from the varying degrees of inhibition on MLEC growth
observed with corresponding concentrations of recombi-
nant human TGF-1.
Determination of tyrosine kinase activity
Confluent HPMC cultured in 35 mm culture dishes un-
der control and experimental conditions were washed twice
with cold PBS and lysed at 4C with 50 mmol N-2-hydroxy-
ethylpiperazine-N-2-ethanesulfonic acid (HEPES) buffer
pH 7.4, containing 1% Triton X-100, 10% glycerol, 1 mmol
dithiothreitol, 1 mmol activated sodium vanadate (100
g/mL) in the presence of proteinase inhibitors (final
concentration 1 mmol benzamidine, 10g/mL leupeptin,
and 2 g/mL pepstatin A). Cell lysates were centrifuged
at 10,000g for 15 minutes at 4C to remove cell debris,
and assayed for tyrosine kinase according to the manu-
facturer’s instructions (Sigma Chemical Co.). Tyrosine
kinase activity is often associated with receptor tyrosine
kinases, such as epidermal growth factor receptor (EGFR).
Thus, EGFR (4U) was used as the positive control and
incubated with emodin (20 g/mL) on ice for 10 minutes
prior to assay.
Determination of FN and Coll-I synthesis by HPMC
using enzyme-linked immunosorbent assay
HPMC were cultured in duplicate in 35 mm culture
dishes under control or experimental conditions for 48
hours. The supernatants were decanted and cells lysed
with 4 mol urea buffer, 20 mmol sodium acetate, pH 6.0
containing 1% (vol/vol) Triton X-100 (100 L). Cell
lysates were desalted, buffer-exchanged into PBS using
Ultrafree Centrifugal Concentrators (Millipore China
Ltd., Hong Kong, China), and assayed for FN and Coll-I
using “in-house” ELISAs [38]. Briefly, 96-well microtiter
plates (Immunlon 2; Dynex Technologies, Inc., Chan-
tilly, VA, USA) were coated in duplicate with FN or
Coll-I (0 to 500 ng/mL) in serial dilutions, or HPMC
supernatant (starting dilution 1:10) or cell lyaste (starting
dilution 1:10) in 15 mmol Na2CO3 and 35 mmol NaHCO3,
pH 9.6 overnight at 4C. Plates were washed three times
with PBS/0.1% Tween-20 in between all steps. The plates
were blocked with 3% bovine serum albumin for 1 hour
at 37C and incubated with primary antibodies (1:1500 for
mouse anti-human FN and 1:1000 for goat anti-human
Coll-I) for 1 hour at 37C. The relevant horseradish per-
oxidase–conjugated secondary antibody was then added
for 1 hour at 37C. Bound immunoglobulins were de-
tected by the addition of Sigma Fast (Sigma Chemical
Co., St. Louis, MO, USA) o-phenylenediamine dihydro-
chloride tablets dissolved according to the manufactur-
er’s instructions, and the absorbance read at a wave-
length of 450 nm. Prior experiments demonstrated 5%
cross-reactivity of primary antibodies with other matrix
proteins. Intra-assay and interassay coefficients of variance
were 4.08  1.5% and 5.7  2.7%, respectively, for FN,
and 6.48  2.9% and 6.95  3.4%, respectively, for Coll-I.
Preparation of cytosolic and membrane extracts
Separation of cytosolic and membrane proteins was
achieved as described by Ma and colleagues [39] with
slight modifications. Briefly, confluent HPMC exposed
to control and experimental conditions for time periods
up to 48 hours were scraped into PBS using a rubber
policeman and collected by centrifugation at 1500g for
10 minutes. Cell pellets were sonicated five times for 10
seconds each period in 200 L PBS containing protease
inhibitors [6], and fractionated by ultracentrifugation at
100,000g for 30 minutes at 4C. Cytosolic proteins ap-
peared in the supernatant, while pelleted membrane pro-
teins were resuspended in 20 mmol sodium acetate, pH
6.0, containing 4 mol urea and 1% Triton X-100 (100L).
The protein concentration of each sample was deter-
mined by a modified Lowry assay (Bio-Rad Pacific, Ltd.)
prior to Western blot analysis.
Preparation of nuclear extract
Confluent HPMC exposed to control and experimen-
tal conditions for 48 hours were scraped into PBS using
a rubber policeman and collected by centrifugation at
1500g for 10 minutes as previously described. Nuclear
extracts were prepared as described by Abmayr and
Workman [40] with slight modifications. Briefly, the cell
pellet was resuspended in 10 mmol HEPES (pH 7.9)
containing 1.5 mmol MgCl2, 10 mmol KCl, 0.5 mmol di-
thiothreitol, and 0.2 mmol phenylmethylsulfonyl fluoride,
and homogenized with a tissue tearor (BioSpec Products,
Inc., Bartlesville, OK, USA) at 12,000 rpm for 2 minutes.
Release of nuclei was monitored under phase contrast
microscopy. Isolated nuclei were separated from cyto-
plasmic contents by centrifugation at 3300g for 15 min-
utes and nuclear proteins extracted with 20 mmol HEPES
(pH 7.9) containing 25% (vol/vol) glycerol, 1.5 mmol
MgCl2, 0.8 mmol KCl, 0.2 mmol EDTA, 0.5 mmol dithi-
othreitol, and 0.2 mmol phenylmethylsulfonyl fluoride.
The samples were then dialyzed against 20 mmol HEPES
buffer (pH 7.9) containing 20% (vol/vol) glycerol, 100
mmol KCl, 0.5 mmol dithiothreitol, and the aforemen-
tioned protease inhibitors. The protein concentration of
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each sample was determined by a modified Lowry assay
(Bio-Rad Pacific, Ltd.) prior to Western blot analysis.
Western blot analyses—Cytosolic and membrane
fractions for PKC activation, total cell lysate for
matrix protein expression, and nuclear extract
for CREB phosphorylation
Whole cell lysates were obtained by solubilizing
HPMC in 4 mol of urea buffer (500 L). Whole cell
lysates, cytosolic, membrane, or nuclear extracts (10 g
total protein content) was denatured in sample buffer
at 95C for 5 minutes and subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Samples were electrophoresed on 7.5% and 10% acryl-
amide gels, respectively, to investigate FN and Coll-I
synthesis, or 12% gels to investigate translation of PKC
and CREB. Proteins were transferred onto nitrocellulose
membrane using a mini-gel transfer system (Bio-Rad
Pacific, Ltd.) at 100 V for 1 hour at 4C. Equal loading
of proteins was confirmed by staining of membranes with
1% (weight/vol) Ponceau S solution. Membranes were
immunoblotted as previously described [35] using respec-
tive primary (1:750 for antibodies to PKC or FN; 1:1000
for antibodies to Coll-I, total CREB, or phosphoCREB)
and secondary antibodies. The bands were visualized by
enhanced chemiluminescence (ECL), semiquantitated by
densitometry using ChemiGenius analysis software (Syn-
gene, Ltd., Cambridge, UK) and unless otherwise stated
expressed as arbitrary densitometric unit (DU). Expres-
sion of PKC, FN, and Coll-I was normalized to actin
synthesis, and phosphoCREB was normalized to total
CREB.
Immunohistochemical staining of HPMC
Control and stimulated HPMC were fixed with cold
acetone/methanol (1:1) for 5 minutes prior to washing
with PBS [41]. Cells were blocked with 3% BSA in PBS
for 1 hour at room temperature followed by washing
with PBS for 30 minutes. Cells were then incubated with
primary antibody (1:50 for antibody to PKC, TGF-1,
or Coll-I; 1:100 for antibody to FN) for 1 hour at 37C
in a humidified chamber. Cells were subsequently washed
with PBS and the relevant fluoroisothiocyanate (FITC)-
conjugated secondary antibody applied for 1 hour at
37C in a darkened humidified chamber. After washing
with PBS the cells were mounted with fluorescence mount-
ant (Dako; Gene Company), and epifluorescence was
viewed using an Axiovert Zeiss 135 inverted microscope.
Statistical analysis
Results are expressed as mean SD. Unless otherwise
stated, all experiments were performed four times using
HPMC from four separate donors. Data from experi-
mental groups and controls were compared by the Stu-
dent t test. P 0.05 was considered statistically significant.
Fig. 1. Representative illustration comparing FN (A and B ), Coll-I (C
and D ), and TGF-1 (E and F ) expression in peritoneal biopsy speci-
mens from patients entering the PD program (renal failure controls) (A,
C, and E) or patients on long-term PD (B, D, and F). Paraffin sections
were subjected to cytochemical staining using the PAP method. Immuno-
reactive products were visualized using diaminobenzidine as chromagen
and counterstained with hematoxylin. Constitutive expression of FN,
Coll-I, and TGF-1 was observed in peritoneal specimens from controls
(A, C, and E, respectively). Peritoneal specimens from patients on long-
term PD demonstrated enhanced FN, Coll-I, and TGF-1 expression
(B, D, and F, respectively), both within the mesothelium (–) and
in the submesothelium (*). Abbreviations are: FN, fibronectin; Coll-I,
collagen type I; TGF-1, transforming growth factor-beta 1; PD, perito-
neal dialysis; PAP, peroxidase-anti-peroxidase. Original magnification,
	400.
RESULTS
Expression of FN, Coll-I, and TGF-1 in
peritoneal biopsies
Cytochemical staining of peritoneal biopsy specimens
demonstrated FN and Coll-I synthesis in mesothelial cells
(Fig. 1). Increased expression of both FN and Coll-I was
noted in chronic PD patients (Fig. 1), compared to those
at the time of initiation of PD (Fig. 1), and was accompa-
nied by increased TGF-1 expression (Fig. 1).
The effects of high glucose concentration and emodin
on HPMC proliferation, expression of PKC, synthesis
of TGF-1, FN, and Coll-I, and the mechanisms leading
to these changes, were investigated using an in vitro
model whereby HPMC were preconditioned in either
physiologic (5 mmol) or elevated (30 mmol) D-glucose
concentrations for up to 1 week in the presence or ab-
sence of emodin. Optimal dose of emodin used in all
experiments was 20 g/mL (IC50 
 71.4  43.6 g/mL)
(Figure 2 A to C). Emodin at this dose did not affect
HPMC thymidine uptake or cell morphology (Fig. 2 A
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Fig. 2. The effects of emodin on HPMC pro-
liferation (A ) and membrane integrity (B ) as
determined by [3H]-thymidine incorporation
and LDH release respectively after incubation
for 24 hours. (C ) Morphology of HPMC with
or without emodin (0, 20, 50, and 100 g/mL)
was assessed under phase contrast microscopy,
respectively; original magnification, 	200).
Emodin at 20 g/mL did not affect HPMC
proliferation, viability, or morphology. (D )
Furthermore, emodin at this dose was not cy-
totoxic to fibroblasts, mesangial cells, epithe-
lial, or endothelial cells, as demonstrated by
insignificant changes in LDH release in the
presence () or absence () of emodin. Ab-
breviations are: HPMC, human peritoneal
mesothelial cells; LDH, lactate dehydroge-
nase. Data represented are mean SD of four
individual experiments. *P  0.001 emodin
vs. control (no emodin); #P  0.0001 emodin
vs. control.
and C). In addition, it was not cytotoxic to HPMC cul-
tured under physiologic (Fig. 2B) or elevated glucose
concentrations, as well as a wide variety of other cell
types, including HPF, HMC, GEC, PTEC, HUVEC,
NHBE, and MeT-5A (Fig. 2D).
Effect of emodin on HPMC proliferation
HPMC proliferation was significantly reduced after
incubation with 30 mmol D-glucose for 48 hours, com-
pared to cells incubated with 5 mmol D-glucose (direct
cell count, 43,200  4100 vs. 31,200  3600 cells, 5 mmol
vs. 30 mmol D-glucose, P  0.001). After 7 days, cells
exposed to 30 mmol D-glucose exhibited 14.28% reduc-
tion in proliferation compared to control cells. Adminis-
tration of emodin to cells cultured under 5 mmol and
30 mmol D-glucose reduced cell proliferation for both
groups transiently (Fig. 3 A and B), resulting in an initial
lag by 2.3  0.3 days and 2.7  0.7 days for 5 mmol
and 30 mmol D-glucose, respectively. Thereafter, cell
proliferation proceeded at the same rate as cells not
exposed to emodin, and they reached confluency 2.4 
1.3 days later than control cells. Cell morphology of
confluent cells remained unaltered in the presence or
absence of emodin (Fig. 3C). Unless otherwise stated,
all data were normalized to g cellular protein.
Effect of emodin on tyrosine kinase and PKC
expression in HPMC under high glucose concentration
Previous studies have demonstrated in human bron-
chial epithelial cells that emodin is a tyrosine kinase
inhibitor [28]. Our results also showed that emodin inhib-
ited the activity of pure tyrosine kinase (EGFR) (Fig. 4).
Elevated glucose concentration induced tyrosine kinase
activity in HPMC, and emodin abrogated this induction
by high glucose concentration (Fig. 4).
Since induction of PKC plays a pivotal role in mediat-
ing the stimulatory effect of glucose on the synthesis of
TGF-1 and matrix proteins in various cells, we exam-
ined PKC expression and the effects of emodin on
PKC activation in our in vitro model. Western blot
analysis showed that 30 mmol D-glucose significantly
increased PKC expression in the cytosolic and mem-
brane fractions in a time-dependent manner, commenc-
ing 12 hours after stimulation (data not shown). Maxi-
mum increase in PKC expression was observed 48
hours after stimulation, in which cytosolic and membrane
fractions increased 1.4-fold and 3.7-fold, respectively,
compared to 5 mmol D-glucose (Fig. 5A, Table 1). While
the addition of emodin to 5 mmol D-glucose had no
effect on PKC expression in either the cytosolic or
membrane fraction (Fig. 5A, lanes 1 and 2; 0.515 0.142
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Fig. 3. Proliferation of HPMC as assessed by
direct cell counting, under 5 mmol (physiologic)
(A) or 30 mmol D-glucose (B), in the presence
() or absence () of emodin. Proliferation
was significantly reduced in HPMC cultured
under 30 mmol D-glucose after 48 hours, com-
pared to cells cultured in 5 mmol D-glucose.
Addition of emodin delayed cell proliferation
by 48 to 72 hours. On reaching confluency, no
change was observed in cell morphology (C) in
the presence (lower panels) or absence (upper
panels) of emodin under 5 mmol (left panels)
or 30 mmol (right panels) D-glucose. HPMC
is human peritoneal mesothelial cell. *P 
0.001, glucose alone vs. glucose and emodin
at the same time point; #P  0.001 5 mmol
vs. 30 mmol D-glucose at the same time point,
original magnification, 	200. Data repre-
sented are mean SD of six individual experi-
ments.
Fig. 4. Inhibition of tyrosine kinase activity by emodin. Cell lysates
obtained under control or experimental conditions after 48 hours of
stimulation were analyzed for tyrosine kinase activity as described.
Purified tyrosine kinase (EGFR, 4U) was used as the positive control.
Results are expressed as mean  SD of three separate experiments.
DU vs. 0.415  0.095 DU, P 
 0.504; and 0.370  0.015
DU vs. 0.331  0.015 DU, P 
 0.487, respectively),
emodin lowered PKC expression in HPMC exposed to
30 mmol D-glucose, resulting in levels similar to baseline
(Fig. 5A, 0.503  0.035 DU and 0.669  0.048 DU for
cytosolic and membrane fraction, respectively, P  0.05
for both). To confirm the inhibitory effect of emodin on
PKC, PKC activation was achieved by exposing HPMC
to PMA for 48 hours (Fig. 5A, lane 6; 0.737  0.154 DU
and 1.718  0.214 DU for cytosolic and membrane frac-
tion, respectively, P  0.05, compared to HPMC not ex-
posed to PMA); the concomitant presence of emodin
and PMA returned PKC activity to basal levels (Fig.
5A, lane 5; 0.588  0.156 DU and 0.437  0.057 DU,
P  0.05, compared to lane 6). Immunohistochemical
analysis confirmed the increase in PKC expression and
its translocation to the cell membrane under elevated
glucose concentration (Fig. 5B), and the abrogation of
these changes by emodin (Fig. 5B).
Effect of glucose, PMA, and emodin on TGF-1
synthesis by HPMC
Immunohistochemical analysis showed enhanced TGF-
1 synthesis in HPMC cultured under 30 mmol D-glucose
with predominant perinuclear staining, compared to cells
cultured under 5 mmol D-glucose (Fig. 6A). While emo-
din has no effect on constitutive TGF-1 expression (Fig.
6A), concomitant addition of emodin ameliorated the
induction of TGF-1 by 30 mmol D-glucose, so that both
the intensity and localization of TGF-1 staining were
similar to control (Fig. 6A).
The secretion of TGF-1 by HPMC was determined
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Fig. 5. Western blot analysis of PKC expression in HPMC. (A ) Cyto-
solic and membrane fractions were purified from 48 hour–stimulated
HPMC as described in Methods, 10 g total protein were subjected to
SDS-PAGE and probed with PKC antibody. Activation of PKC-
was associated with translocation to the cell membrane (lanes 3 and
6). Emodin did not alter PKC expression under 5 mmol D-glucose,
but ameliorated the increase in PKC expression in the membrane
fraction induced by 30 mmol D-glucose or PMA. One representative
blot of four is shown. (B ) Immunohistochemical analysis of HPMC for
PKC under (a) 5 mmol D-glucose, (b) 5 mmol D-glucose and emodin,
(c) 30 mmol D-glucose, or (d) 30 mmol D-glucose and emodin. Cells
were cultured under control or experimental conditions for 48 hours prior
to fixation with cold acetone/methanol and were subsequently probed
with specific antibody to PKC (arrow). D-glucose (30 mmol) induced
membrane translocation of PKC (depicted by arrow). Emodin sup-
pressed 30 mmol D-glucose–induced PKC expression to basal levels,
but did not affect constitutive PKC expression. Original magnification,
	600. Abbreviations are: PKC, protein kinase C ; HPMC, human
peritoneal mesothelial cells; SDS-PAGE, sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis; PMA, phorbol 12-myristate 13-acetate.
using a specific TGF-1 ELISA, which demonstrated
that the majority of TGF-1 (95%) in culture superna-
tants under control or experimental conditions was de-
tected only after acid-activation, implying that it was
synthesized mainly in its latent form. TGF-1 synthe-
sized by cells cultured in 5 mmol or 30 mmol D-glucose
showed a time-dependent increase (Fig. 6B). Exposure
of HPMC to 30 mmol D-glucose resulted in significantly
higher supernatant concentrations of “latent” TGF-1
at 24 hours and 48 hours compared to cells cultured
under physiologic glucose concentration (3.72 0.29 pg/g
cellular protein vs. 2.13  0.23 pg/g cellular protein at
24 hours, P  0.001; and 4.30  0.50 pg/g cellular
protein vs. 2.65 0.32 pg/g cellular protein at 48 hours,
P  0.001). Exposure of HPMC to 30 mmol mannitol
or L-glucose did not alter TGF-1 synthesis significantly
Table 1. Densitometric intensity of cytosolic and cell
membrane–associated PKC- under control
and experimental conditions
Densitometric intensity of PKC- corrected to
actin intensity arbitrary units
Total Cytosolic Membrane
PKC- PKC- PKC-
5 mmol D-glucose 0.8850.147 0.5150.142 0.3700.015
5 mmol D-glucose 
emodin 0.7460.144 0.4150.095 0.3310.015
30 mmol D-glucose 2.1040.241a 0.7340.157a 1.3700.297a
30 mmol D-glucose
emodin 1.1720.214b 0.5030.035b 0.6690.048b
PMA 2.4550.187a 0.7370.154a 1.7180.214a
PMA  emodin 1.0250.298b 0.5880.156b 0.4370.057b
Abbreviations are: PKC-, protein kinase C-; PMA, phorbol 12-myristate
13-acetate. All samples stimulated for 48 hours were normalized to the
“housekeeping” protein actin. Results are expressed as meanSD of four sepa-
rate experiments.
aP  0.05 when experimental conditions compared with 5 mmol D-glucose
bP  0.05 when comparing results in the presence or absence of emodin
compared to 5 mmol D-glucose (data not shown). Emo-
din did not affect the constitutive secretion of TGF-1
under 5 mmol D-glucose, but it abrogated the induction
by 30 mmol D-glucose (2.25 0.15 pg/g cellular protein
at 24 hours, P 0.001; 2.96 0.33 pg/g cellular protein
at 48 hours, P  0.001) (Fig. 6B). PMA markedly in-
creased TGF-1 secretion compared to 5 mmol D-glu-
cose (6.92  2.98 pg/g cellular protein vs. 2.21  0.21
pg/g cellular protein, P  0.0001) (Fig. 6C), but such
increase was completely abrogated by emodin (2.58 
0.21 pg/g cellular protein, P 0.0001). Prior incubation
of HPMC with neutralizing antibody to TGF-1 (1g/mL)
resulted in an 81.4% reduction of PMA-induced TGF-1
secretion (3.41 0.31 pg/g cellular protein, P 0.0001).
No further change was observed with higher concentra-
tions of neutralizing antibody to TGF-1 (data not shown).
Concomitant exposure of HPMC to PMA, neutralizing
antibody to TGF-1 and emodin resulted in supernatant
TGF-1 levels similar to those when HPMC was exposed
to 5 mmol D-glucose alone.
Three to five percent of the total TGF-1 secreted by
HPMC under control or experimental conditions was in
the “active” form and was detectable by ELISA without
prior acid activation. Their bioactivity was confirmed
using the mink lung epithelial cell growth inhibition assay
(Table 2). This bioactive fraction increased 3.60- and
4.12-fold when the cells were cultured in 30 mmol D-glu-
cose for 24 hours and 48 hours, respectively (Table 2).
Mannitol or L-glucose (30 mmol) showed no effect (data
not shown). In comparison, stimulation of HPMC with
PMA for 24 hours and 48 hours induced bioactive TGF-1
by 6.69- and 7.50-fold, respectively, compared to cells
exposed to 5 mmol D-glucose. Emodin ameliorated the
increase in bioactive TGF-1 induced by elevated glu-
cose or PMA (Table 2). To ascertain whether residual
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Fig. 6. (A) Immunohistochemical analysis of HPMC for TGF-1 ex-
pression under (a) 5 mmol D-glucose, (b) 5 m D-glucose and emodin,
(c) 30 mmol D-glucose, or (d) 30 mmol D-glucose and emodin. Cells
were cultured under control or experimental conditions for 48 hours
prior to fixation with cold acetone/methanol and were subsequently
probed with specific antibody to TGF-1. Emodin suppressed 30 mmol
D-glucose–induced TGF-1 expression to basal levels, but did not affect
constitutive TGF-1 expression. Original magnification, 	600. (B ) Ef-
fect of glucose and emodin on TGF-1 secretion by HPMC. HPMC
were cultured in 5 mmol D-glucose in the presence () or absence ()
of emodin, or in 30 mmol D-glucose with () or without () emodin
for time periods up to 48 hours. TGF-1 content was measured in the
supernatant (N 
 4). Emodin had no effect on TGF-1 secretion by
HPMC cultured under 5 mmol (physiologic) D-glucose, but abrogated
the increase in TGF-1 secretion induced by 30 mmol D-glucose to
levels similar to cells exposed to physiologic glucose concentration.
Table 2. Effect of D-glucose, PMA, and emodin on
TGF-1 bioactivity
TGF-1 bioactivity pg/g
cellular protein
T 
 24 h T 
 48 h
5 mmol D-glucose 0.0680.01 0.0720.01
5 mmol D-glucose  emodin 0.0650.02 0.0750.02
30 mmol D-glucose 0.2450.06a 0.2970.03a
30 mmol D-glucose  emodin 0.0630.01b 0.0790.02b
PMA 0.4550.09a 0.5410.12a
PMA  emodin 0.0660.04b 0.0890.07b
PMA is phorbol 12-myristate 13-acetate. Results are expressed as meanSD
of four separate experiments.
aP  0.05 comparing experimental conditions with 5 mmol D-glucose
bP  0.05 comparing results in the presence or absence of emodin
PMA  emodin remaining in the conditioned media after
incubation with HPMC could induce MLEC TGF-1 syn-
thesis, and thus alter MLEC growth, TGF-1 levels in
the conditioned media were determined using ELISA
before and after administration to MLEC. Our results
showed that the residual PMA  emodin had no signifi-
cant effect on MLEC TGF-1 synthesis or cell growth
(data not shown).
Effect of glucose, PMA, and emodin on FN and Coll-I
synthesis by HPMC
Using “in-house” FN and Coll-I ELISA, we observed
up-regulation of FN synthesis and secretion after stimu-
lation of HPMC with 30 mmol D-glucose for 48 hours,
compared to cells cultured under 5 mmol D-glucose (36.3
3.6 vs. 157.8  9.1 ng/g cellular protein for 5 mmol and
30 mmol D-glucose, respectively, for secreted FN; 19.4 
5.2 vs. 79.4  12.2 ng/g cellular protein for 5 mmol and
30 mmol D-glucose, respectively, for cell-associated FN,
P  0.05 for both) (Table 3). FN synthesis was also
significantly increased upon PKC activation (217.0 
21.8 and 91.5  15.3 ng/g cellular protein for secreted
and cell-associated FN, respectively, P  0.05 compared
to control). Emodin had no effect on FN synthesis under
physiologic glucose concentration, but ameliorated both
glucose-induced and PMA-stimulated FN synthesis. The
inhibitory effect of emodin was similar to TGF-1 neu-
*P  0.001, 30 mmol D-glucose vs. 5 mmol D-glucose at T 
 24 and
48 hours. (C ) Effects of PMA-stimulated PKC activation, emodin, and
neutralizing TGF-1 antibody on TGF-1 secretion by HPMC. HPMC
were stimulated with PMA (100 nmol) in the presence or absence of
emodin or TGF-1 neutralizing antibody for 48 hours. TGF-1 secretion
was assessed in the supernatant (N 
 4). Emodin suppressed PMA-
stimulated TGF-1 secretion to basal levels, and its suppressive effect
was more pronounced compared to TGF-1 neutralizing antibody. Ab-
breviations are: HPMC, human peritoneal mesothelial cells; TGF-1,
transforming growth factor-1; PMA, phorbol 12-myristate 13-acetate;
PKC, protein kinase C.
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Table 3. Determination of secreted and cell-associated FN and Coll I in HPMC under control and experimental conditions
Concentration ng/g cellular protein
Secreted Cell-associated Cell-associated
FN FN Coll-I
5 mmol D-glucose 36.33.6 19.45.2 16.88.1
5 mmol D-glucose  emodin 34.63.9 19.74.3 17.84.6
5 mmol D-glucose  normal IgG 35.04.8 18.96.2 17.22.1
5 mmol D-glucose  TGF-1 Ab 37.72.6 19.24.7 16.55.1
30 mmol D-glucose 157.89.1a 79.412.2a 56.312.5a
30 mmol D-glucose  emodin 39.85.4b 22.45.3b 18.44.6b
30 mmol D-glucose  normal IgG 159.310.5a 77.210.5a 57.18.3a
30 mmol D-glucose  TGF-1 Ab 43.78.2b 25.58.1b 20.45.9b
PMA 100 nmol 21721.8a 91.515.3a 70.410.2a
PMA  emodin 47.19.2b 26.57.3b 19.47.5b
PMA  normal IgG 210.319.7a 89.611.7a 67.98.1a
PMA  TGF-1 Ab 54.210.5a,b 32.97.5a,b 28.53.1b
Abbreviations are: FN, fibronectin; PMA, phorbol 12-myristate 13-acetate; IgG, immunoglobulin G; TGF-1 Ab, transforming growth factor-beta 1 antibody.
Enzyme-linked immunosorbent assay (ELISA) was used to analyze cell supernatants and lysates for FN and Coll-I obtained 48 hours of experimental stimulation.
Results are expressed as meanSD of four separate experiments.
aP  0.05 comparing experimental conditions with 5 mmol D-glucose
bP  0.05 comparing 30 mmol D-glucose or PMA in the presence or absence of emodin or TGF-1 Ab
tralizing antibody, and was more marked with elevated
glucose concentration than PMA (Table 3).
Elevated glucose concentration and PMA also modu-
lated the translation of Coll-I. Coll-I was not constitu-
tively secreted from HPMC cultured under 5 mmol D-glu-
cose, nor was Coll-I secretion altered by high glucose
concentration or PMA stimulation (data not shown).
D-glucose (30 mmol) induced the expression of only the
cell-associated Coll-I, compared to 5 mmol D-glucose
(56.3  12.5 vs. 16.8  8.1 ng/g cellular protein, P 
0.05), and such stimulation was abrogated by emodin.
Exposure of HPMC to PMA markedly increased cell-
associated Coll-I (70.4  10.2, P  0.05 compared to
control), which was again ameliorated by emodin and
anti-TGF-1 antibody (Table 3). Western blot analysis
corroborated the results on FN and Coll-I by ELISA
(Fig. 7 A and B).
Localization of FN and Coll-I in HPMC cultured un-
der control or experimental conditions for periods up to
1 week was assessed using immunohistochemical staining
(Fig. 7C). Significantly increased intracellular FN and
Coll-I was observed after 48 hours of 30 mmol D-glucose
stimulation (data not shown), while induction of FN and
Coll-I deposition into the extracellular milieu was ob-
served at 72 hours, and the latter progressed to form an
extensive matrix by 1 week (Fig. 7C). Emodin reduced
the increased matrix synthesis induced by high glucose
concentration to near basal levels, and the ameliorating
effect was evident even in HPMC exposed to 30 mmol
D-glucose for 1 week. Despite the reduction in matrix
synthesis by emodin, cell attachment was unaffected,
as determined by cell counting (62,000  967 cells/cm2,
62,630  1010 cells/cm2, 61,567  1009 cells/cm2, and
61,789  1034 cells/cm2 for HPMC cultured under 5 mmol
D-glucose, 5 mmol D-glucose with emodin, 30 mmol
D-glucose, and 30 mmol D-glucose with emodin, respec-
tively; P 
 0.70, 0.69, and 0.78, respectively, when com-
pared to 5 mmol D-glucose alone after 1 week of culture
under control or experimental conditions). Control ex-
periments using 30 mmol mannitol or L-glucose did not
show any significant change in FN or Coll-I expression
compared to 5 mmol D-glucose (data not shown).
Effect of glucose and emodin on
CREB phosphorylation
CRE of the FN gene has been demonstrated to medi-
ate increased FN synthesis in mesangial cells induced
by high glucose concentration or TGF-1 [31, 32]. We
therefore investigated CREB phosphorylation in nuclear
extracts isolated from HPMC cultured under physiologic
and elevated glucose concentrations using Western blot
analysis. Anti-phosphoCREB (pCREB) antibody used
in this study was raised against the phosphoserine in a
portion of the CREB protein that shared 100% homol-
ogy with the phosphoserine site of the CREB-related
protein activated transcription factor-1 (ATF-1) [42].
Consequently, ATF-1 could also be detected by this anti-
body. Our results demonstrated that while total CREB
content remained unaltered under control and experi-
mental conditions, 30 mmol D-glucose increased CREB
phosphorylation at serine 133 by 1.84-fold, compared to
5 mmol D-glucose (0.46  0.25 DU vs. 0.25  0.09 DU).
This was accompanied by a 1.36-fold increase in ATF-1
at serine 63 (Fig. 8A, lanes 1 and 3). PMA also activated
CREB and ATF-1 (Fig. 8A, lane 6; 0.57  0.01 and
0.22  0.01 DU, respectively). In comparison, emodin
significantly reduced the induction of CREB and ATF-1
phosphorylation by both high glucose and PMA (Fig.
8A, lanes 4 and 5, respectively). In control experiments,
neither 30 mmol mannitol nor L-glucose altered phos-
phorylation of CREB or ATF-1, as compared to 5 mmol
D-glucose (data not shown).
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Fig. 7. Western blot analysis of FN and Coll-
I synthesis by HPMC showing the effects of
glucose, PMA, and emodin. (A ) Culture su-
pernatant or total cell lysate was extracted
from HPMC after 48 hours of stimulation,
subjected to SDS-PAGE, and probed with an-
tibodies to FN or Coll-I. Emodin ameliorated
the increase in FN (secreted and cell-associ-
ated) and Coll-I (cell-associated only) synthe-
sis induced by 30 mmol D-glucose and PMA
to control levels. One representative blot of
four separate experiments is shown. (B ) The
intensity of the detected bands of secreted FN
( ), cell-associated FN (), and cell-associ-
ated Coll-I () were analyzed by densitomet-
ric scan, normalized to actin, and expressed
as arbitrary units. (C ) Immunohistochemical
analysis of HPMC for FN and Coll-I under
control or experimental conditions. HPMC
were cultured in 5 mmol D-glucose (a, e, i, m),
5 mmol D-glucose and emodin (b, f, j, n), 30
mmol D-glucose (c, g, k, o), or 30 mmol D-
glucose and emodin (d, h, l, p) for 72 hours
(a through h) or one week (i through p) prior
to fixation with cold acetone/methanol. Cells
were subsequently stained for FN (a through
d, i through l) or Coll-I (e through h, m through
p). Cytoplasmic and extracellular deposition
of FN, the latter in fibrillar form, was noted
after exposure to 5 mmol D-glucose for up to
one week (a vs. i), but was accelerated when
cells were exposed to 30 mmol D-glucose (c
and k). Fibrillar FN deposition was evident
72 hours after exposure to elevated glucose
concentration (c). D-glucose (30 mmol) also
induced Coll-I synthesis in a time-dependent
manner similar to FN (e, g, m, o). Addition
of emodin to 30 mmol D-glucose for 72 hours
reduced cytoplasmic and fibrillar FN, as well
as Coll-I expression, although perinuclear
staining of FN and Coll-I was still evident (c
and d, g and h, respectively). An extensive
matrix was deposited by cells cultured in 30
mmol D-glucose for one week, containing pre-
dominantly FN (k) and to a lesser extent Coll-I
(o). Both were suppressed to near basal levels
when emodin was present concomitantly (l
and p). Original magnification, 	400. Abbre-
viations are: FN, fibronectin; Coll-I, collagen
type I; HPMC, human peritoneal mesothelial
cells; PMA, phorbol 12-myristate 13-acetate;
SDS-PAGE, sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis.
DISCUSSION
Mesothelial cells line the peritoneal cavity and consti-
tute a protective bioactive barrier that plays a key role
in maintaining the structural and functional integrity of
the peritoneal membrane [1]. In addition, the normal
synthesis of peritoneal membrane constituents by perito-
neal mesothelial cells is essential for peritoneal preserva-
tion. Surgical, chemical, or infective injury to the meso-
thelium initiates pathologic processes that culminate in
disruptions of both structural and functional integrity
of the peritoneal membrane [2, 10–12]. Conventional
peritoneal dialysis solutions contain glucose at high con-
centrations as the osmotic agent. Continuous exposure
of the peritoneum to these unphysiologic solutions is
associated with abnormalities in cellular proliferation,
synthesis of cytokines and growth factors, and increased
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Fig. 8. Western blot analysis showing the effects of glucose, PMA, and
emodin on CREB and ATF-1 phosphorylation by HPMC after 48 hours
of stimulation. (A ) Nuclear extracts were subjected to SDS-PAGE and
probed with antisera to phosphoCREB and phosphoATF-1. While no
significant difference was observed for total CREB expression under
different experimental conditions, emodin reduced 30 mmol D-glucose-
or PMA-induced CREB and ATF-1 phosphorylation, but had no effect
on the constitutive activation of the transcription factors. One represen-
tative blot of three separate experiments is shown. (B ) The intensity
of the detected bands of phosphoCREB () and phosphoATF-1 ()
were analyzed by densitometric scan, normalized to CREB, and ex-
pressed as arbitrary units. Abbreviations are: PMA, phorbol 12-myris-
tate 13-acetate; CREB, cAMP-responsive element binding protein; ATF-1,
activating transcription factor-1.
synthesis of matrix components by the mesothelial cells
and deposition of matrix within the submesothelium [3,
9, 13–15]. Increased matrix deposition is precedent to
peritoneal fibrosis and a major contributing factor to
failure of peritoneal transport functions. In line with pub-
lished work, we have demonstrated accumulation and
deposition of FN and Coll-I within peritoneal biopsies
obtained from chronic PD patients accompanied by en-
hanced TGF-1 expression, compared to biopsies ob-
tained from new PD patients. While previous studies have
implicated prolonged exposure of the peritoneum to glu-
cose at high concentrations as a major contributing factor
for these profibrotic processes, there is as yet no effective
means to ameliorate or prevent the detrimental effects
of concentrated glucose on peritoneal mesothelial cells.
HPMC cultured in vitro provide a relevant in vitro
model to study the effect of PD solutions on cell prolifer-
ation and function, since previous in vitro studies have
demonstrated that they possess the same immunohisto-
chemical markers as peritoneal mesothelial stem cells
[43]. In addition to the suppressive effect of high glucose
concentration on HPMC proliferation [13], in this study
we demonstrated for the first time that high ambient glu-
cose concentration induced PKC autocrine phosphory-
lation of CREB and ATF-1 in HPMC, and induced
TGF-1 mediated fibrillar and cytoplasmic FN and Coll-I
synthesis. Activation of PKC, exemplified by its trans-
location from the cytosol to the cell membrane in HPMC
by concentrated glucose, also up-regulated FN and
TGF-1 gene transcription [30], but not that of Coll-I
(unpublished data). Our results also showed that the
synthesis of laminin and collagen types III and IV was
similarly induced by concentrated glucose (unpublished
data). These effects were a result of elevated D-glucose
concentration, per se, rather than hyperosmolality, since
there was no significant effect with concentrated manni-
tol or L-glucose compared to physiologic control. Similar
effects of concentrated glucose have been reported in
human mesangial cells, which have also been related to
PKC activation [44–46]. It has been suggested that glu-
cose metabolism, either through the pentose phosphate
shunt or through glycerolipid production, leads to an
increase in diacylglycerol and, subsequently, activation
of PKC. In this context, Ha et al [13] have demonstrated
that high glucose–induced diacylglycerol and PKC up-
regulation mediated TGF-1 and FN synthesis by perito-
neal mesothelial cells.
Activation of PKC has been shown to modulate tran-
scription factors, for example, c-fos and c-jun, through
the activated protein-1 (AP-1) binding site. Promotor
regions of TGF-1, FN, and Coll-I have also been dem-
onstrated to contain the AP-1 binding consensus sequence,
which may therefore represent one mechanism by which
high ambient glucose concentration up-regulates TGF-1
and matrix synthesis [47, 48]. On the other hand, it has
been reported that PKC activation and CREB phosphor-
ylation are involved in elevated glucose–mediated induc-
tion of FN transcription in human mesangial cells, medi-
ated through a consensus CRE located at 170 bp of
the FN gene [31, 32]. Our results in the present study
showed that high glucose–induced FN synthesis was also
associated with phosphorylation of CREB in HPMC.
Phosphorylation of CREB at serine 133 appears to be
essential for its activation, and can occur through numer-
ous signaling pathways, for example, PKA stimulation,
adenyl cyclase pathway, p42/44 MAP kinase, p38 kinase,
or induction of intracellular Ca2 [49–51]. Unlike mesan-
gial cells [32, 52], and in concordance with a previous
study on FN synthesis [13], we have found that concen-
trated glucose was able to induce FN and Coll-I synthesis
in HPMC in the absence of exogenous TGF-1 or fetal
calf serum (FCS). These results suggest that concen-
trated D-glucose per se plays a pivotal role in the induc-
tion of matrix synthesis in HPMC.
Other investigators have reported that emodin may
possess antiproliferative and/or anti-inflammatory activities
in mesangial cells, bronchial epithelial cells, lung squamous
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cell carcinoma cell line, and T lymphocytes, at concentra-
tions that vary from 1.35 g/mL (5 mol) to 100 g/mL
(370 mol) [25, 26, 28]. The observed variability in the
cellular effects of emodin may be attributed to species
differences in its phytologic origin, or heterogeneity of
response in different cell types. To address these issues,
we have used highly purified emodin from a single batch
and have examined its effects on cell proliferation and
viability in different cell types. A prerequisite to further
experiments in vivo is that the emodin species being tested
must not adversely affect cell viability. Our data showed
that emodin at 20g/mL (74mol) was nontoxic to HPMC
exposed to either physiologic or elevated D-glucose con-
centration, as evidenced by assessment of cell prolifera-
tion and LDH release. We have, therefore, used this dose
in subsequent experiments. Furthermore, our emodin at
this concentration did not induce membrane damage in a
wide variety of cell types, including peritoneal fibroblasts
and other cells that may be involved in matrix synthesis
or tissue fibrosis. It is of interest to note that emodin at 20
g/mL did not affect cell proliferation in 80% confluent
HPMC, yet proliferation was transiently inhibited in
newly seeded cells cultured under control and experi-
mental conditions. This differential effect may suggest
that subconfluent cells could be more sensitive to the effects
of emodin. The antimitogenic effect of emodin in relation
to cell density is currently being studied. A major finding
in this study was that emodin consistently suppressed
concentrated glucose-induced TGF-1 bioactivity, FN,
and Coll-I synthesis in HPMC. These ameliorating ef-
fects of emodin on TGF-1 and matrix synthesis were
genuine and not related to differences in cell number,
since our results showed similar cell numbers under con-
trol and experimental conditions at confluence when the
experiments were performed. Nevertheless, the observed
reduction in mesothelial cell proliferation in the presence
of 30 mmol D-glucose or emodin suggested alterations
in the dynamic processes of cell turnover, which could
be of particular relevance in the regenerative response
to injury. In animal models of diabetic nephropathy,
reduction of mesangial proliferation by antimitogenic
agents was accompanied by amelioration of glucose-
induced matrix synthesis [53]. It remains to be inves-
tigated whether the ameliorating effect of emodin on
D-glucose–induced matrix synthesis by HPMC might be
causally related to its precedent antimitogenic effect that
lasted for approximately 48 hours. It is noteworthy that,
despite the initial inhibition of HPMC proliferation,
emodin had no effect on the constitutive synthesis of
TGF-1 and matrix by HPMC under 5 mmol D-glucose.
Our data demonstrated that the abrogation of elevated
D-glucose–induced TGF-1 and matrix synthesis in
HPMC by emodin was mediated through the inhibition
of PKC activation. The results suggest a more pronounced
inhibitory effect with emodin compared to neutralizing
antibody to TGF-1, since the addition of emodin re-
sulted in the complete suppression of PMA-induced
TGF-1 and matrix synthesis. Since both soluble and
cell-associated FN were decreased by emodin, it is likely
that emodin suppressed FN synthesis, rather than inhib-
iting its accumulation and deposition within the extracel-
lular milieu. Although we have demonstrated that PKC
activation plays an important role in D-glucose–induced
matrix synthesis in HPMC, it remains possible that other
PKC isoforms may be involved in the pathogenesis of
peritoneal fibrosis, as has been reported in diabetic ne-
phropathy [54]. In this regard, we are investigating the
potential effects of emodin on other isoforms of PKC in
the presence of different concentrations of D-glucose.
Emodin inhibits different protein kinases, including
casein kinases 1 and 2, PKA, and tyrosine kinase [55, 56].
Whether emodin can inhibit other kinases, such as
MAPK and c-jun NH2-terminal kinase (JNK), is cur-
rently being investigated. The inhibitory action of emo-
din is dependent on its ability to penetrate into the active
site of the enzymes [29]. Crystallography studies by Bat-
tistutta et al [29] demonstrated that emodin enters the
nucleotide-binding site of casein kinase II in the proxim-
ity of the site normally occupied by the natural cosub-
strate. This led to structural changes in the N-terminal
lobe of the enzyme, resulting in the inability of casein
kinase II to bind to its cosubstrate [29]. It is speculated
that similar molecular mechanisms may explain the in-
hibitory action of emodin on PKC in HPMC.
CONCLUSION
We have demonstrated that emodin can effectively
ameliorate the detrimental effects of concentrated
D-glucose on HPMC, namely the induction of TGF-1
bioactivity and matrix synthesis, through inhibition of
PKC activation and CREB phosphorylation, without
compromising cellular viability. Further studies will need
to be be undertaken in an animal model of peritoneal
fibrosis to confirm our in vitro findings. Amelioration
of TGF-1 mediated tissue fibrosis using emodin may
provide important clinical potential in the long-term
preservation of structural and functional integrity of the
peritoneal membrane in patients on PD.
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